We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Aprea Therapeutics Inc (APRE) USD0.001

Sell:$2.19 Buy:$2.22 Change: $0.04 (1.79%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.04 (1.79%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.04 (1.79%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The Company's lead product, eprenetapopt (APR-246), is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator that is being developed in an oral dosage form.

Contact details

535 Boylston St
United States
+1 (609) 5104718

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$45.08 million
Shares in issue:
21.47 million
United States
US dollar

Key personnel

  • Christian Schade
    Chairman of the Board, President, Chief Executive Officer
  • Scott Coiante
    Chief Financial Officer, Senior Vice President, Secretary
  • Lars Abrahmsen
    Senior Vice President, Chief Scientific Officer
  • Eyal Attar
    Senior Vice President, Chief Medical Officer
  • Gregory Korbel
    Senior Vice President, Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.